

Odette S Reifsnider

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7522827/odette-s-reifsnider-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

5

papers

21

citations

3

h-index

4

g-index

6

ext. papers

57

ext. citations

5.6

avg, IF

1.61

L-index

#	Paper	IF	Citations
5	Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG Outcome Trial. <i>American Journal of Kidney Diseases</i> , 2021 ,	7.4	2
4	Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. <i>BMJ Open Diabetes Research and Care</i> , 2021 , 9,	4.5	2
3	Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 791-799	6.7	5
2	Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 3910	3.7	5
1	Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study. <i>Farmeconomia E Percorsi Terapeutici</i> , 2017 , 18,	0	7